I have been through one internal appeal already and would like to do the next one properly.
I suspect the usual explanation for this is wrong, or at least incomplete.
I am aware this may have a boring answer. I would still like the boring answer stated clearly.
Can someone derive this rather than assert it?
Answer first: a compounded preparation is made for an individual under a prescription and is not an approved product, so it carries neither the release testing nor the pharmacovigilance of one.
Compounding is the preparation of a medicine for an individual patient in response to a prescription, where an approved product is unsuitable. It sits outside the approval framework by design rather than by omission.
| Line | Brand, insured | Compounded, subscription | Research-grade, self-tested |
|---|---|---|---|
| Product | Copay × 12 | Monthly fee × 12 | Vials × unit price |
| Consultation | Covered or copay | Bundled | Not applicable |
| Monitoring labs | Often covered | Usually not | Self-funded |
| Independent testing | Not applicable | Optional | Essential; per lot |
| Shipping | Pharmacy | Included | Per order |
| Dominant cost | Copay structure | Subscription fee | Testing |
Stated carefully, additives are the other divergence. Preparations combining an active with vitamins or other agents are not equivalent to the approved product and have not been studied in that combination.
Regulatory warnings have specifically addressed salt forms differing from the approved active moiety in this therapeutic area.
A compounded preparation is unapproved by definition, which is a statement about the framework rather than about the facility.
Ask for the certificate of analysis on the lot. A serious facility has one.
Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.
Shop standardsThe relevant distinction is between compounding for an individual patient and compounding at scale, which are regulated differently.
Facility quality varies enormously and is the practical determinant of what you receive. The relevant questions are about sterility assurance, potency testing and beyond-use dating.
Ask for the certificate of analysis on the compounded lot. A serious facility will have one; the request itself is informative.
Prohibitions on compounding essential copies of commercially available products are explicit in the relevant regulatory frameworks, with shortage listings as the usual exception.
Facility quality is the dominant variable and cannot be assessed from a website.
Check the beyond-use date and what it was based on.
Salt forms and additives are the usual point of divergence and are worth asking about specifically.
Regulators generally prohibit compounding what is essentially a copy of a commercially available product, with a shortage listing being the usual exception that permits it temporarily.
Salt forms matter: a compounded preparation using a different salt from the approved product is not the same active moiety, and that has been the specific object of regulatory warnings.
The caveat is that the legal and regulatory position differs by jurisdiction and nothing here is legal advice.
The framework is jurisdiction-specific. Check yours rather than a general answer.
Stated carefully, this is an area where the legal position and the quality question are separate and both matter.
Beyond-use dates on compounded sterile preparations are set by standards that depend on the preparation environment and are much shorter than a manufactured product's shelf life.
Compounding is defined in regulation as preparation for an individual patient under prescription and is distinguished from manufacturing by scale and by the patient-specific requirement.
Compounded means unapproved by definition. That is structural, not pejorative.
The short version: legitimate under a prescription within defined limits, unapproved by definition, and quality depends entirely on the facility.
A compounded preparation has no marketing authorisation, no batch release by a qualified person and no pharmacovigilance obligation attached to it. That is the structural difference from a licensed product.
Beyond-use dating for compounded sterile preparations is governed by published standards keyed to the compounding environment.
Nothing here is medical advice.
Ask which salt form. A different salt is a different active moiety.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.